Role of ceruloplasmin in inflammation: increased serum ceruloplasmin levels during inflammatory conditions and its possible relationship with anti-inflammatory agents.
Serum ceruloplasmin (CPN) levels under different types of acute and chronic experimentally-induced inflammatory conditions in rats and the effect of anti-inflammatory drugs viz. oxyphenylbutazone and hydrocortisone on serum CPN levels were investigated. Significant increase of serum CPN levels was observed in all experimental animal models with induced inflammatory conditions. Treatment with oxyphenylbutazone and hydrocortisone failed to inhibit the raised serum CPN levels. The concurrent increase of serum CPN level during induced inflammatory conditions suggest the involvement of serum CPN as one of the body's inbuilt defensive mechanism against noxious responses or inflammation. It is suggested that the increased serum CPN levels may be a complimentary factor associated with inflammatory conditions.
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001169:Arthritis, Experimental / Q000097:blood; D002351:Carrageenan; D002570:Ceruloplasmin / Q000378:metabolism*; D004487:Edema / Q000097:blood; D006099:Granuloma / Q000097:blood; D006854:Hydrocortisone / Q000627:therapeutic use; D007249:Inflammation / Q000097:blood* / Q000188:drug therapy; D008297:Male; D010113:Oxyphenbutazone / Q000627:therapeutic use; D051381:Rats
D000893:Anti-Inflammatory Agents; D002351:Carrageenan; D002570:Ceruloplasmin; D010113:Oxyphenbutazone; D006854:Hydrocortisone